Back to Authors

Crestanello, Juan

Mayo Clinic

WinnMed

Citations 2

Longitudinal Analysis of Heparin-Binding Protein (HBP) and Serum Amyloid a Protein (SAA) Versus Interleukin 6 (IL-6), C-Reactive Protein (CRP), and Procalcitonin (PCT) During Both the Acute Postoperative Period and Recovery at Three Months From Non-emergen
Laudański, Krzysztof , Ahmed, Ahmed Sayed, Mahmoud, Mohamed A., Gad, Hossam , Harris, Benjamin R.E., Smith, Ryan, Zhu, Dandan, Elgazar, Abdelhamed , Vasishta, Anil, Ognjen, Gajic, Diedrich, Daniel A. , Crestanello, Juan, Smith, Ryan J. , Gad, Hossam , Mahmoud, Mohamed A. , Harris, Benjamin R.E.

Clinical Medicine Insights: Cardiology | July 11, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/11795468261462607 Get It

Variability in novel inflammatory markers (HBP and SAA) post-surgery could indicate ongoing perioperative inflammation. This pilot cohort study collected blood from 99 patients undergoing elective cardiac surgery at baseline, 24 hours, 7 days, and 3 months post-surgery. Inflammatory markers (HBP, SAA, PCT, CRP, IL-6) were measured with a point-of-care device. Demographic and clinical data were extracted from health records. Serum SAA increased significantly in the acute postoperative phase (M e [IQR];SAA baseline =81.1[87] vs SAA 24hr= 232.65[88.02];U[72]=2343,p<0.0001), remained elevated at 7 days (Me 7d =252.6[88.56];U[57]=1484,p<0.0001) and were still more pronounced than baseline at t 3m (Me 3m =118.44[101.52];U[38]=448,p=0.0008). HBP showed a significant rise at seven days (HBP baseline =45[26;89] vs HBP 7d =121[69.75;224.5]; U[56]=805,p<0.0001) then returned to near baseline by t 3m (Me 3m =32.5[15.75;98.5]). Traditional inflammatory markers PCT, CRP, and IL-6 demonstrated a rapid increase at t 24h and plateaued at t 7d . None of the biomarkers showed variability at baseline or postoperatively with preoperative status or postoperative complications. Cluster analysis of the inflammatory markers at 24 hours (t 24h ) identified distinct subgroups. Cluster #1-patients with a modest increase in all markers; Cluster#2 characterized with a robust increase in IL-6; Cluster #3 showed increase in CRP and decline in HBP; Cluster #4 showed a modest increase in IL-6 and decline in HBP; Cluster #5 represented a decline in both CRP and SAA. Patients in these clusters differ with respect to age, pre-existing peripheral artery disease, and borderline differences in perioperative acetaminophen use. SAA and HBP remain elevated longer than IL-6, CRP, and PCT after surgery, suggesting that inflammation may persist beyond 3 months.
Management of Liver Cirrhosis in Percutaneous and Surgical Cardiac Interventions
Spadaccio, C., Mehta, Krishna, Pisani, Angelo , Osho, Asishana, Juarez‐Casso, Fernando, Alvaro, Domenico, Arif, Imran, Panza, Antonio, Vester, Russell S., Louis, Louis B., Sundt, Thoralf M., Crestanello, Juan, Alvaro, Domenico , Osho, Asishana A. , Spadaccio, Cristiano , Pisani, Angelo , Osho, Asishana , Juarez-Casso, Fernando, Alvaro, Domenico , Panza, Antonio , Louis, Louis B , Sundt, Thoralf , Crestanello, Juan A , Rose, David , Spadaccio, Cristiano , Nenna, Antonio , Juarez-Casso, Fernando M. , Arif, Imran, Vester, Russell Samuel , Sundt, Thoralf M. , Rose, David

Journal of the American Heart Association | February 24, 2026 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/jaha.125.045147 Get It

The systemic impairment that accompanies liver cirrhosis is known to carry a significant burden on death and postoperative complications in cardiovascular interventions. This review analyzes the impact of liver cirrhosis on short‐ and long‐term outcomes after cardiac surgery and percutaneous procedures, providing an evidence‐based guidance in the decision‐making process and perioperative management of these patients. Several parameters should be considered by the heart teams when assessing eligibility, indications for intervention, and perioperative management of these patients. Life expectancy, long‐term procedural outcomes, Child–Pugh or the Model for End‐Stage Liver Disease score, presence of gastroesophageal varices and hepatic venous pressure gradient were extrapolated as the main determinants in decision making in patients with cirrhosis. Assessment and treatment of gastroesophageal varices is mandatory. Hepatic venous pressure gradient values >20 mm Hg preclude patients from a surgical approach. Considering the poor prognosis of advanced liver cirrhosis, futile treatments should be avoided. A multidimensional heart team approach involving surgical, cardiologic, anesthesiologic, hepatological, and medical considerations is recommended.